San Francisco AIDS Foundation news story
“Breakthrough” HIV infections among people receiving long-acting injectable lenacapavir for PrEP in two major clinical trials were a topic of discussion at CROI 2026.
Across two large clinical trials testing long-acting lenacapavir for PrEP, with thousands of cisgender women, men who have sex with men, and gender diverse people who have sex with men, a total of four individuals seroconverted during the study period while receiving on-time medication injections.
Why did lenacapavir fail to protect a small number of people from acquiring HIV in the study?, questioned one clinician from the University of Colorado during the presentation’s Q&A. “I think patients want to know, and I think we need that information soon. I’ve already had someone who declined to use lenacapavir because of the breakthrough infections.”
Read the full news story here.
Source : San Francisco AIDS Foundation
Related HIV and Co-Infections News
-
[Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates
-
University of Manchester: Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug lenacapavir
-
EL PAÍS: US aid cuts collapse Malawi’s LGBTQ+ health services as volunteers scramble to fill the void
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.